Competition intensifies in already crowded multiple sclerosis space
05/09/19 -"Novartis’ Arzerra is all set to enter the fast-growing/crowded MS space (likely in 2020) banking on superior clinical data vs. Sanofi’s Aubagio. While this would dent the sales of Aubagio, Novartis’ ..."
Pages
58
Language
English
Published on
05/09/19
You may also be interested by these reports :
12/09/19
Merck held an investors’ day. Summarising findings and discussions, Merck confirmed our positive view. Management delivered what it had announced ...
05/09/19
Novartis’ Arzerra is all set to enter the fast-growing/crowded MS space (likely in 2020) banking on superior clinical data vs. Sanofi’s Aubagio. ...
16/08/19
Our last Novozymes (Add, Denmark) Teaser was aptly titled, ‘Crude-driven Novozymes’. That proved right, again and sadly on the way down. This, in ...
23/07/19
Sanofi (Add, France) has been a story of disorientation, as we have repeatedly asserted. Some solid assets rekindle phases of hope every now and then ...